Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

被引：0

作者：

Federica Marmorino

Lisa Salvatore

Cecilia Barbara

Giacomo Allegrini

Lorenzo Antonuzzo

Gianluca Masi

Fotios Loupakis

Beatrice Borelli

Silvana Chiara

Maria Chiara Banzi

Emanuela Miraglio

Domenico Amoroso

Francesco Dargenio

Andrea Bonetti

Angelo Martignetti

Myriam Paris

Daniela Tomcikova

Luca Boni

Alfredo Falcone

Chiara Cremolini

机构：

[1] Azienda Ospedaliero-Universitaria Pisana,Department of Medical Oncology

[2] Ospedale Civile di Livorno,Division of Medical Oncology

[3] Pontedera Hospital,Department of Oncology

[4] Azienda Ospedaliero-Universitaria Careggi,undefined

[5] Istituto Oncologico Venoto,undefined

[6] National Institute for Cancer Research,undefined

[7] Arcispedale Santa Maria Nuova,undefined

[8] IRCCS,undefined

[9] S. Croce General Hospital,undefined

[10] Ospedale Versilia–Lido di Camaiore,undefined

[11] Dipartimento oncologico AUSL 6 Livorno–Piombino,undefined

[12] Department of Medical Oncology Mater Salutis Hospital Legnago,undefined

[13] Dipartimento Oncologico AUSL 7,undefined

[14] S.O.C. Oncologia–Ospedale degli Infermi,undefined

[15] Fondazione Sandro Pitigliani,undefined

[16] Clinical Trial Coordinating Center,undefined

[17] AOU Careggi,undefined

[18] Istituto Toscano Tumori,undefined

来源：

British Journal of Cancer | 2017年 / 116卷

关键词：

bevacizumab beyond progression; LDH; predictive marker;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：318 / 323

页数：5

共 50 条

[1] Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
Marmorino, Federica
Salvatore, Lisa
Barbara, Cecilia
Allegrini, Giacomo
Antonuzzo, Lorenzo
Masi, Gianluca
Loupakis, Fotios
Borelli, Beatrice
Chiara, Silvana
Banzi, Maria Chiara
Miraglio, Emanuela
Amoroso, Domenico
Dargenio, Francesco
Bonetti, Andrea
Martignetti, Angelo
Paris, Myriam
Tomcikova, Daniela
Boni, Luca
Falcone, Alfredo
Cremolini, Chiara
BRITISH JOURNAL OF CANCER, 2017, 116 (03) : 318 - 323
[2] Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
Marmorino, F.
Cremolini, C.
Loupakis, F.
Salvatore, L.
Masi, G.
Barbara, C.
Dargenio, F.
Miraglio, E.
Ginocchi, L.
Antonuzzo, L.
Moretto, R.
Schirripa, M.
Chiara, S.
Banzi, C.
Amoroso, D.
Bonetti, A.
Martignetti, A.
Paris, M.
Boni, L.
Tomcikova, D.
Falcone, A.
ANNALS OF ONCOLOGY, 2016, 27
[3] Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
Marmorino, F.
Cremolini, C.
Loupakis, F.
Antoniotti, C.
Barbara, C.
Dargenio, F.
Miraglio, E.
Masi, G.
Salvatore, L.
Schirripa, M.
Borelli, B.
Marcucci, L.
Antonuzzo, L.
Chiara, S.
Banzi, C.
Amoroso, D.
Bonetti, A.
Martignetti, A.
Paris, M.
Boni, L.
Tomcikova, D.
Falcone, A.
ANNALS OF ONCOLOGY, 2016, 27 : 103 - 103
[4] Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study
Marmorino, Federica
Cremolini, Chiara
Loupakis, Fotios
Barbara, Cecilia
Dargenio, Francesco
Miraglio, Emanuela
Masi, Gianluca
Salvatore, Lisa
Marcucci, Lorenzo
Antonuzzo, Lorenzo
Chiara, Silvana
Banzi, Chiara
Schirripa, Marta
Amoroso, Domenico
Bonetti, Andrea
Martignetti, Angelo
Paris, Myriam
Boni, Luca
Tomcikova, Daniela
Falcone, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
You, Xia-Hong
Wen, Can
Xia, Zi-Jin
Sun, Fan
Li, Yao
Wang, Wei
Fang, Zhou
Chen, Qing-Gen
Zhang, Lei
Jiang, Yu-Huang
Wang, Xiao-Zhong
Ying, Hou-Qun
Zong, Zhen
FRONTIERS IN ONCOLOGY, 2019, 9
[6] Treatment beyond progression in metastatic colorectal cancer: to double or not to double the dose of bevacizumab?
Bochis, Ovidiu-Vasile
Vlad, Catalin
Cainap, Calin
Achimas-Cadariu, Patriciu
Sur, Daniel
Havasi, Andrei
Vidrean, Andreea
Muresan, Alexandra
Piciu, Andra
Bota, Madalina
Constantin, Anne-Marie
Tat, Tiberiu
Maniu, Dana
Crisan, Ovidiu
Cioban, Cosmin Vasile
Balacescu, Ovidiu
Coza, Ovidiu
Balacescu, Loredana
Marta, Monica Mihaela
Cainap, Simona
JOURNAL OF BUON, 2020, 25 (02): : 875 - 883
[7] Effectiveness of bevacizumab beyond progression in patients with metastatic colorectal cancer - data from the clinical TKK registry
Schnell, R.
Musch, R.
Broszeit-Luft, S.
Harde, J.
Kopfmann, S.
Jaenicke, M.
Marschner, N.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 101 - 102
[8] The Continuation of Bevacizumab Following Disease Progression in Patients with Metastatic Colorectal Cancer Offers a Survival Benefit
Samelis, Georgios E.
Ekmektzoglou, Konstantinos A.
Tsiakou, Andriani
Konstadoulakis, Manousos
HEPATO-GASTROENTEROLOGY, 2011, 58 (112) : 1968 - 1971
[9] Should Bevacizumab Be Continued Beyond Progression in Colorectal Cancer?
Grothey, Axel
Arnold, Dirk
Ellis, Lee M.
CURRENT COLORECTAL CANCER REPORTS, 2008, 4 (03) : 139 - 143
[10] Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center
Cainap, Calin
Bochis, Ovidiu-Vasile
Vlad, Catalin
Popita, Raluca
Achimas-Cadariu, Patriciu
Havasi, Andrei
Vidrean, Andreea
Dranca, Alexandra
Piciu, Andra
Constantin, Anne-Marie
Tat, Tiberiu
Dana, Maniu
Crisan, Ovidiu
Cioban, Cosmin Vasile
Balacescu, Ovidiu
Coza, Ovidiu
Balacescu, Loredana
Marta, Monica Mihaela
Bota, Madalina
Cainap, Simona
FRONTIERS IN PHARMACOLOGY, 2021, 12

← 1 2 3 4 5 →